Uncategorized

Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases

Sitryx Therapeutics announces that Eli Lilly & Company has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases.

Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases Read More »

Burning Rock Announces Receipt of Notification from NASDAQ – Jan 04, 2024

Burning Rock Biotech Limited announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC dated December 29, 2023, indicating that for the last 30 consecutive business days, the closing bid price for the Company’s American depositary shares was below the minimum bid price of

Burning Rock Announces Receipt of Notification from NASDAQ – Jan 04, 2024 Read More »

Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA

Kuros Biosciences announced three advancements related to its MagnetOs portfolio of products: specifically positive results from the MAXA level 1 clinical trial comparing standalone MagnetOs to autograft in a real world patient population in the challenging posterolateral fusion procedure, and two 510 clearances from the U.S. Food and Drug Administration related to its MagnetOs family

Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA Read More »

Scroll to Top